Got sick of scrolling to the bottom of the other thread on my phone , and figured the title could use a change in tense..
Completion of recruitment due in June / early July. Analysis should follow not long after the last patient finishes treatment 12 weeks later (potentially earlier if they happen to heal prior to twelve weeks). Progressive data (still blinded to include standard of care group) seems to tick the right boxes (at least to the degree that you can take away from blinded data).
The company has additional indications in the pipeline. Success in this trial enables recommencement of ema approval (expected to run more smoothly this time under actually competent new management). It enables phase 3 discussions in the us and opens the doors wide for prospective partners.
The new management team post 2016 have demonstrated a commitment to actually communicating with shareholders.
It’s all coming up milhouse...
The run has begun, and it has a good way to go yet prior to results....
- Forums
- ASX - By Stock
- Run has begun
Got sick of scrolling to the bottom of the other thread on my...
-
- There are more pages in this discussion • 17 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add DLM (ASX) to my watchlist
(20min delay)
|
|||||
Last
3.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $7.227M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
DLM (ASX) Chart |
Day chart unavailable
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Michael Thurn, CEO & MD
Michael Thurn
CEO & MD
SPONSORED BY The Market Online